{"disease":{"id":"urinary-bladder-cancer-muscle-invasive","name":"urinary bladder cancer muscle invasive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03924895","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":595,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05946369","title":"Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Ain Shams University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}